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???????
??????????：Amantadine is a drug used for patients with Parkinson’s disease （PD） and vascular par-
kinsonism （VP）. These patients often have lower urinary tract symptoms （LUTS） and nocturnal polyuria
（NP）. Thus, we investigated the effect of amantadine on these in parkinsonian patients.
???????：Twenty-two patients with LUTS, including 13 with PD and nine with VP, were recruited. We 
performed a urinary questionnaire, frequency-volume chart, and residual urine （RU） measurement before 
and after daily administration of 150 mg and 300 mg amantadine.
???????：Before amantadine administration, mean daytime urinary frequency was 9.07（standard error 
［SE］, 0.64）, nighttime urinary frequency 2.89 （0.24）, urinary urgency per week 24.2 （6.69）, urge inconti-
nence per month 15.1 （9.94）, urine volume per void 145.6 （12.6） mL, and residual urine volume 12.5 （6.30） 
mL. After daily 150 mg amantadine administration, mean daytime and nighttime urinary frequency, urinary 
urgency, and urge incontinence decreased to 6.9 （0.42）, 1.97 （0.21）, 13.0 （3.58）, and 14.2 （10.2）, respective-
ly, and urine volume per void increased to 174.1 （11.3） mL. NP （N＝8） was ameliorated in six patients. No 
patient had side effects. After daily 300 mg amantadine administration （N＝8）, mean daytime and nighttime 
urinary frequency, urinary urgency, and urge incontinence decreased to 6 .90 （0.33）, 1 .69 （0.10）, 5 .88
（1.61）, and 2.31 （0.61）, respectively, and urine volume per void increased to180.2 （15.0） mL. NP （N＝4） 
was ameliorated in two patients. One patient developed hallucination, and two patients developed flashing 
sensation.
??????????：Amantadine has beneficial effects on LUTS and NP in patients with VP and PD.
???? ????： Amantadine, Lower urinary tract 
dysfunction, Nocturnal polyuria, 
Parkinson’s disease, Vascular par-
kinsonism
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Lower urinary tract symptoms（LUTS）are common 
non-motor dysfunctions in patients with Parkinson’s 
disease（PD）1〜7）. In LUTS, storage symptoms, such as 
daytime urinary frequency, nighttime urinary frequen-
cy（nocturia）, urinary urgency, and urge incontinence, 
are common in PD patients3,5〜7）. Some studies report 
that nighttime urinary frequency is the most common 
among the storage symptoms in PD patients3,5〜7）.
Vascular parkinsonism （VP） accounts for 2.5–5％ of 
parkinsonism cases8）. LUTS is common in patients with 
VP, as well as in those with other diseases of Parkin-
son’s syndrome and cerebrovascular diseases. A recent 
systematic review showed that the patients with VP 
present more commonly with symmetrical gait difficul-
ties, postural instability, falls, dementia, pyramidal 
signs, pseudobulbar palsy, and LUTS （urinary inconti-
nence） than patients with PD9）.
LUTS impairs the quality of life and also disturbs 
many areas of life, such as sleep and daily-activity, and 
generally results in a risk of serious adverse conse-
quences such as fall, fracture, depression, and cognitive 
impairment10〜12）. These disturbances and risks may be 
higher in patients with PD or VP, because these pa-
tients commonly have not only LUTS but also motor, 
sleep, and cognitive disturbances.
In addition, recent reports show that nocturnal poly-
uria （NP） is a cause of LUTS （nighttime urinary fre-
quency） in older patients13）. NP is reported to occur in 
some neurological diseases, such as VP14）and PD15）, 
which contributes to LUTS and increases the risk of 
adverse consequences due to LUTS. Thus, LUTS and 
NP in patients with PD or VP must be prevented suffi-
ciently. However, there is no disease-specific medica-
tion for LUTS and NP in patients with PD or VP.
Amantadine is l-amino-adamantanamine, a salt of 
the symmetric 10-carbon primary amine, and is an an-
tiviral for the treatment of influenza and a drug using 
for patients with PD and VP. Although its precise 
mechanism of action is uncertain, it thought to be 
based on interaction with dopamine, by enhancing the 
release and inhibiting the reuptake of dopamine and by 
changing dopamine receptor affinity, and on NMDA 
glutamate receptor blockade, which normalizes the ac-
tivities of the glutamatergic corticostriatal and subtha-
lamic-pallidal pathways16）. In addition, amantadine is 
reported to have other various clinical effects such as 
reducing levodopa-induced dyskinesia 17）, improving 
pathological gambling and punding17）, ameliorating de-
pression18）, preventing postoperative central sensitiza-
tion19）, and reducing pain19）. Additionally, amantadine is 
thought to have noradrenaline, serotonergic, anti-cho-
linergic, and anti-opioid effects 17〜21）. It is also known 
that these effects are associated with neuro-muscular 
control of the lower urinary tract system. Actually, in 
clinical application, we experience that the treatment of 
amantadine ameliorates not only parkinsonism but also 
LUTS and NP, simultaneously.
Thus, we hypothesized that amantadine ameliorates 
LUTS and NP and investigated the effect of amanta-
dine on them in patients with PD or VP.
????????????????????
Twenty-two parkinsonian patients with LUTS, in-
cluding 11 male and 11 female, with a mean age of 72.5 
years（standard deviation ［SD］, 6.4）, were included in 
these studies. Of these patients, 13 had Parkinson’s dis-
ease （PD；median Hoehn & Yahr 2.78）, and nine had 
vascular parkinsonism （VP）. PD and VP were diag-
nosed after clinical examination, magnetic resonance 
imaging（MRI）according to clinical diagnostic crite-
ria22,23）, as well as the results of cardiac I-metaiodoben-
zylguanidine （MIBG） testing. Furthermore, in cases of 
PD, it was possible to confirm the initial clinical impres-
sion after patients were started on parkinsonian medi-
cation, and their responses could be assessed. Patients 
with severe cognitive impairment, major depression/
psychiatric disorder, or other diseases known to influ-
ence lower urinary tract function, such as diabetes 
mellitus, spondylosis, and prostate hypertrophy, as well 
as those receiving medication for lower urinary tract 
problems, were excluded.
We performed a detailed urinary questionnaire, fre-
quency-volume chart/bladder diary, and measurement 
of residual urine （RU） by echography before and one 
month after daily administration of 150 mg amantadine. 
In addition, we addressed an insufficient effect for 
150 mg amantadine in cohort of patients with an in-
crease of amantadine. One month after daily adminis-
tration of 300 mg amantadine, we repeated the ques-
tionnaire, the chart/diary, and the measurement of RU. 
We also observed any side effects or changes of neuro-
logical and mental manifestations. This study was ap-
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proved by the Ethics Committee of Chiba University 
and Dokkyo Medical University and was conducted 
according to the principles of the Declaration of Hel-
sinki. All participants gave their informed consent be-
fore commencement of the studies.
Symptoms of LUTS were evaluated with a non-vali-
dated questionnaire that is used routinely in our de-
partments. Storage symptoms consisted of urinary ur-
gency, daytime urinary frequency, nighttime urinary 
frequency（nocturia）, and urge/stress/mixed inconti-
nence. Urinary frequency was defined as more than 
eight times per daytime period and twice or more per 
night. Voiding symptoms consisted of hesitancy, slow 
stream, intermittency, straining, feeling of incomplete 
emptying, and urinary retention. Volumes voided, as 
well as the time of each micturition and information 
about fluid intake, were recorded in a frequent-volume 
chart（bladder diary）for 2–3 successive days. Noctur-
nal polyuria（NP）was defined as a nocturnal urine 
volume exceeding 33％ of the 24-h urine output. Noc-
turnal urine volume was defined as the total volume of 
urine passed between the time the individual goes to 
bed with the intention of sleeping and the time of wak-
ing with the intention of rising. The terminology of 
LUTS conformed to the standards proposed by the In-
ternational Continence Society24）.
Statistical analyses were performed using commer-
cial software（Excel Statistics Ver. 6 .0；Esumi Inc., 
Tokyo, Japan）. The results of the evaluation of LUTS, 
bladder daily volume, and residual urine volume before 
and after amantadine administration were compared 
by a paired t-test（parametric）or Wilcoxon signed-
rank test（nonparametric）. Differences in the results in 
each group were assessed with ANOVA and multiple 
comparisons. Associations between categorical vari-
ables were examined by a Chi-square test for indepen-
dence. Significant results were considered with caution 
for p values marginally less than 0.05.
???????
LUTS, NP, and RU in patients with PD and VP
Before amantadine administration, daytime urinary 
frequency was a complaint in 15 patients（68.2％, PD：
VP＝53.8：88.9％；P＝0.039）, and mean daytime uri-
nary frequency was 9 . 0 7（standard error ［SE］, 
0.64）；nighttime urinary frequency was a complaint in 
19 patients（86.4％, PD：VP＝92.3：77.8％；not sig-
nificant ［ns］）, and mean nighttime urinary frequency 
was 2.89（SE, 0.24）；urinary urgency was a complaint 
in 17 patients（77.3％, PD：VP＝84.6：66.7％；ns）, and 
mean urinary urgency per week was 24.2（SE, 6.69）；
urge incontinence was a complaint in 13 patients（59.1
％, PD：VP＝61.5：55.6％；ns）, and mean urge incon-
tinence per month was 15.1（SE, 9.94）；hesitancy was 
a complaint in six patients（27.3％, PD：VP＝7.7：55.6
％；P＝0.013）, and mean hesitancy per week was 1.61
（SE, 0.69）；slow stream was a complaint in eight pa-
tients（36.4％, PD：VP＝15.4：66.7％；P＝0.013）, and 
mean slow stream per week was 1.86（SE, 0.72）；in-
termittency was a complaint in four patients（18.2％, 
PD：VP＝7.7：33.3％；ns）, and mean intermittency per 
week was 0.52（SE, 0.25）；straining was a complaint in 
five patients（22.7％, PD：VP＝7.7：44.4％；P＝0.043）, 
and mean straining per week was 1.95（SE, 0.89）；feel-
ing of incomplete emptying was a complaint in seven 
patients（31.8％, PD：VP＝15.4：55.6％；P＝0.046）, and 
mean feeling of incomplete emptying per week was 
1.38（SE, 0.60）；and no patients had urinary retention.
A frequent-volume chart（bladder diary）was com-
pleted in 18 patients（81.8％, PD：VP＝9：9）. Mean 
urine volume per void was 145.6（SE, 12.6）mL, includ-
ing mean daytime urine volume per void 136 .9（SE 
11.6）mL and mean nighttime urine volume per void 
187.3（SE 21.3）mL. Eight patients（44.4％, PD：VP＝
66.7：22.2％；ns）had nocturnal polyuria, and mean 
nocturnal polyuria index（NPI）was 30.0（SE, 2.47）.
Mean residual urine volume was 12.5（SE 6.30）mL.
LUTS after amantadine administration
One month after daily administration of 150 mg 
amantadine（N＝21）, daytime urinary frequency was 
alleviated in 16 patients（76.2％）, unchanged in four
（19.0％, including three patients without daytime uri-
nary frequency）, and aggravated in one（4.8％）. Mean 
daytime urinary frequency was decreased significantly 
to 6.9（SE 0.42, P＝0.002）. Nighttime urinary frequen-
cy was alleviated in 10 patients（47.6％）, unchanged in 
10（47.6％, including 3 patients without nighttime uri-
nary frequency）, and aggravated in one（4.8％）. Mean 
nighttime urinary frequency was decreased significant-
ly to 1.97（SE 0.21,（P＝0.001） （Figure 1）. Urinary 
urgency was alleviated in 15 patients（71 .4％）and 
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in three patients（14.3％）, unchanged in 17（80.9％, 
including 16 patients without strain）, and aggravated 
in one（4.8％）. However, mean hesitancy per week, 
slow stream per week, intermittency per week, and 
strain per week tended to decrease, but these changes 
were not significant. Feeling of incomplete emptying 
was alleviated in three patients（14 . 3％）and un-
changed in 18（85.7％, including 14 patients without 
slow stream）. Mean feeling of incomplete emptying per 
week was decreased significantly to 0.81（SE 0.47, P＝
0.049） （Figure 2）.
One month after daily administration of 300 mg 
amantadine in PD patients showing an insufficient ef-
fect with daily 150 mg amantadine（N＝8）, compared 
with before amantadine treatment, daytime urinary 
frequency was alleviated in five patients（62.5％）and 
unchanged in three（37 .5％, including two patients 
unchanged in six（47.6％, including five patients with-
out urinary urgency）. Mean urinary urgency per week 
was 13.0（SE 3.58）, which tended to decrease, but this 
change was not significant. Urge incontinence was alle-
viated in eight patients（38.1％）and unchanged in 13
（61 . 9％, including 9 patients without urge inconti-
nence）. Mean urge incontinence per month was 14 .2
（SE 10.2）, which tended to decrease, but this change 
was not significant. Hesitancy was alleviated in two pa-
tients（9.5％）, unchanged in 18（85.7％, including 13 
patients without hesitancy）, and aggravated in one
（4.8％）. Slow stream was alleviated in three patients
（14.3％）, unchanged in 17（80.9％, including 13 pa-
tients without slow stream）, and aggravated in one
（4.8％）. Intermittency was alleviated in three patients
（14.3％）and unchanged in 18（85.7％, including 17 
patients without intermittency）. Strain was alleviated 
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????????　 Daytime urinary frequency and nighttime urinary frequency 
before and after amantadine administration.
Amantadine ameliorates daytime and nighttime urinary frequency and 
urgency significantly in patients with PD or VP.
????????　 Feeling of incomplete emptying and residual urine before and 
after amantadine administration.
Amantadine ameliorates feeling of incomplete emptying as a post-voiding 
symptom significantly, but did not change residual urine volume in 
patients with PD or VP.
Amantadine for LUTS and NP in PD and VP
（over 10％）in nine patients（50.0％）, was unchanged 
in six（33.3％）, and decreased in three（16.7％）. Mean 
urine volume per void was 174.1（SE, 11.3）mL, includ-
ing mean daytime urine volume per void 162 .6（SE 
10.1）mL and mean nighttime urine volume per void 
206.8（SE 19.5）mL, and tended to increase but not 
significantly （Figure 3）. NP （N＝8） was alleviated in 
six patients（75.0％）, unchanged in one（12.5％）, and 
aggravated in one（12.5％）. Mean NPI was 25.1（SE, 
2.66）and tended to decrease but not significantly（Fig-
ure 4）.
After daily administration of 300 mg amantadine, 
compared with before amantadine treatment, mean 
urine volume per void and mean daytime urine volume 
per void increased（over 10％）in five patients（83.3
without daytime urinary frequency）. Nighttime urinary 
frequency was alleviated in three patients（37.5％）and 
unchanged in five（62.5％, including two patients with-
out nighttime urinary frequency）. Urinary urgency 
was alleviated in six patients（75.0％）and unchanged 
in two（25.0％, including one patient without urinary 
urgency）. Urge incontinence was alleviated in five pa-
tients（62.5％）and unchanged in three（37.5％, includ-
ing three patients without urge incontinence）. Mean 
daytime urinary frequency was 6.90（SE 0.33）, mean 
nighttime urinary frequency 1.69（SE 0.10）, and mean 
urinary urgency per week 5 .88（SE 1 .61）；all were 
decreased significantly（P＝0.002 ,＜0.001 , 0 .005 , re-
spectively）. Mean urge incontinence per month was 
2 .31（SE 0 .61）, which tended to decrease, but this 
change was not significant. Hesitancy, slow stream, in-
termittency, strain, and feeling of incomplete emptying 
also were alleviated or unchanged. Mean hesitancy per 
week, slow stream per week, intermittency per week, 
strain per week, and feeling of incomplete emptying 
per week tended to decrease, but these changes were 
not significant
NP after amantadine administration
One month after daily administration of 150 mg 
amantadine, mean urine volume per void（N＝19）in-
creased（over 10％）in 13 patients（68.4％）and was 
unchanged in six（31.6％）. Mean daytime urine volume 
per void（N＝19）increased（over 10％）in 14 patients
（73.7％）and was unchanged in six（26.3％）. Mean 
nighttime urine volume per void（N＝18）increased
??（1） （2015） 25
????????　 Daytime and nighttime void volume before and after 
amantadine administration.
Amantadine tended to increase both daytime and nighttime urine 
volume per void in patients with PD or VP.
????????　 Nocturnal polyuria index （NPI） before and 
after amantadine administration.
Amantadine tended to decrease NPI and ameliorated NP
（NPI ＞33％）in each patients with PD or VP.
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patients with PD. Although our study evaluated a 
small group, there was a difference between LUTS in 
patients with PD and VP. In PD, it is well known that 
storage symptoms are common, resulting from central 
disinhibition of the micturition reflex and abnormal 
bladder sensation by a PD specific pathology, and that 
voiding symptoms are not common, although voiding 
disorder frequently exists in the background1〜7）. Our 
results are similar with the findings in the previous 
studies. On the other hand, details of LUTS in patients 
with VP and the pathophysiology are not well known. 
There is no report that evaluates the voiding symp-
toms, except indwelling catheter in patients with VP. 
In the central nervous system, there is a brain lesion 
associated with both storage function and voiding func-
tion27）. It is thought that various LUTS occur according 
to the vascular lesion in patients with VP. In our study, 
daytime urinary frequency and many kinds of voiding 
symptoms are more common in patients with VP than 
in patients with PD. These findings suggest that pa-
tients with VP present more commonly with not only 
storage symptoms but also with voiding symptoms 
than patients with PD.
In our study, amantadine tended to increase both 
daytime and nighttime urine volume per void and sig-
nificantly ameliorated daytime and nighttime urinary 
frequency and urinary urgency in patients with PD or 
VP. Amantadine also ameliorated feeling of incomplete 
emptying as a post-voiding symptom in those patients. 
Amantadine is reported have various effects such as 
activation of dopamine action, blockage of the gluta-
minergic （NMDA） receptor, activation of noradrena-
line （NA） action, activation of serotonin （5HT） action, 
blockage of opioid receptors（particularly d  receptor）, 
and blockage of cholinergic receptors 16〜21）. Single ad-
ministration of a drug with dopamine action, such as 
levodopa or a dopamine agonist, is reported to acceler-
ate micturition reflex short-term after the administra-
tion28〜31）. However, single administration of apomor-
phine elicited a dose- and time-dependent biphasic 
effect on bladder storage function32）. It is also shown 
that chronic repeated administration of levodopa ame-
liorates storage disorder33）. Thus, chronic repeated do-
pamine action by amantadine is associated with amelio-
ration of storage and voiding disorders in patients with 
PD or VP. An NMDA receptor blocker inhibits spinal 
％）and was unchanged in one（16.7％）（N＝6）. Mean 
nighttime urine volume per void increased（over 10％）
in three patients（50.0％）, was unchanged in two（33.3
％）, and decreased in one（16.7％）（N＝6）. Mean urine 
volume per void was 180.2（SE, 15.0）mL, including 
mean daytime urine volume per void 165.3（SE 14.9）
mL and mean nighttime urine volume per void 208.1
（SE 19.5）mL, and tended to increase, but these chang-
es were not significant （Figure 3）. NP（N＝4）was al-
leviated in two patients（50.0％）and unchanged in two
（50.0％）. Mean NPI was 28.0（SE, 3.84）and tended to 
decrease, but this change was not significant （Figure 
4）
RU after amantadine administration
One month after daily administration of 150 mg 
amantadine, RU volume was 6.84（SE, 3.63）and tend-
ed to decrease but not significantly. One month after 
daily administration of 300 mg amantadine, RU volume 
was 15.0（SE, 3.60）and tended to decrease, but this 
change was not significant.
Other symptoms after amantadine administration
After daily administration of 300 mg amantadine, one 
patient with mild cognitive dysfunction developed ex-
acerbation of hallucination, and two patients developed 
flashing sensation.
??????????
Our study reports, for the first time, that amantadine 
ameliorates LUTS in patients with PD or VP, and, in 
detail, it ameliorates daytime urinary frequency, night-
time urinary frequency, and urinary urgency, as stor-
age symptoms, and the feeling of incomplete emptying, 
as a voiding symptom. Amantadine also ameliorated 
NP in patients with PD or VP. In addition, these results 
show that there is a difference between LUTS in pa-
tients with PD and VP. Patients with VP present more 
commonly with daytime urinary frequency, as a stor-
age symptom, and hesitancy, slow stream, straining, 
and feeling of incomplete emptying, as voiding symp-
toms.
There are a few reports that compare LUTS in pa-
tients with PD and VP. A recent systematic review9） 
and some reports25,26） show that patients with VP pres-
ent more commonly with urinary incontinence than 
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nary bladder distension by blocking glutaminergic ex-
citatory transmission in the central micturition reflex 
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by amantadine is associated with amelioration of stor-
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Amantadine also tended to decrease NPI and amelio-
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In conclusion, amantadine has beneficial effects on 
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in patients with PD and VP, as well as for motor dys-
function.
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